Neuropathic pain of peripheral origin: Advances in pharmacologic treatment

被引:111
作者
Galer, BS
机构
[1] WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, SEATTLE, WA USA
[2] WASHINGTON UNIV, SCH MED, DEPT NEUROL, SEATTLE, WA USA
关键词
D O I
10.1212/WNL.45.12_Suppl_9.S17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A variety of mechanisms may generate pain resulting from injury to the peripheral nervous system. None of these mechanisms is disease-specific, and several different pain mechanisms may be simultaneously present in any one patient, independent of diagnosis. Diagnosis of neuropathic pain is often easily made from information gathered on neurologic examination and from patient history. Evidence of sensory disturbances elicited on examination combined with laboratory tests confirming injury to peripheral nerve establishes the diagnosis of neuropathic pain. Although treatment of neuropathic pain may be difficult, optimum treatment can be achieved if the neurologist has a complete understanding of the therapeutic options, the mainstay of which is pharmacotherapy. Selection of an appropriate pharmacologic agent is by trial and error since individual responses to different agents, doses, and serum levels are highly variable. An adequate trial for each agent tried is key to pharmacologic treatment of neuropathic pain. Tricyclic antidepressants are first-line agents, although other drugs, including anticonvulsants, local anesthetic antiarrhythmics, clonidine, opioids, and certain topical agents, also offer pain relief in some patient populations. The novel antidepressants venlafaxine and nefazodone are potentially useful new drugs that are better tolerated than tricyclic antidepressants.
引用
收藏
页码:S17 / S25
页数:9
相关论文
共 53 条
[41]   SYMPTOMATIC TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY WITH CARBAMAZEPINE (TEGRETOL) - DOUBLE BLIND CROSSOVER TRIAL [J].
RULL, JA ;
QUIBRERA, R ;
GONZALEZ.H ;
CASTANED.OL .
DIABETOLOGIA, 1969, 5 (04) :215-&
[42]   CONCENTRATION RESPONSE RELATIONSHIP IN PAROXETINE TREATMENT OF DIABETIC NEUROPATHY SYMPTOMS - A PATIENT-BLINDED DOSE-ESCALATION STUDY [J].
SINDRUP, SH ;
GRODUM, E ;
GRAM, LF ;
BECKNIELSEN, H .
THERAPEUTIC DRUG MONITORING, 1991, 13 (05) :408-414
[43]   ANALGESIC CONCENTRATIONS OF LIDOCAINE SUPPRESS TONIC A-DELTA AND C-FIBER DISCHARGES PRODUCED BY ACUTE INJURY [J].
TANELIAN, DL ;
MACLVER, MB .
ANESTHESIOLOGY, 1991, 74 (05) :934-936
[44]  
TAYLOR K, 1995, P ANN SCI M AM PAIN
[45]   QUANTITATIVE SOMATOSENSORY THERMOTEST - A KEY METHOD FOR FUNCTIONAL-EVALUATION OF SMALL CALIBER AFFERENT CHANNELS [J].
VERDUGO, R ;
OCHOA, JL .
BRAIN, 1992, 115 :893-913
[46]   AMITRIPTYLINE VERSUS PLACEBO IN POSTHERPETIC NEURALGIA [J].
WATSON, CP ;
EVANS, RJ ;
REED, K ;
MERSKEY, H ;
GOLDSMITH, L ;
WARSH, J .
NEUROLOGY, 1982, 32 (06) :671-673
[47]  
WATSON CP, 1993, CLIN THER, V15, P10
[48]   TOPICAL CAPSAICIN AS AN ADJUVANT ANALGESIC [J].
WATSON, CPN .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1994, 9 (07) :425-433
[49]  
WILTON TD, 1974, S AFR MED J, V48, P869
[50]   TRANSDERMAL CLONIDINE VERSUS PLACEBO IN PAINFUL DIABETIC NEUROPATHY [J].
ZEIGLER, D ;
LYNCH, SA ;
MUIR, J ;
BENJAMIN, J ;
MAX, MB .
PAIN, 1992, 48 (03) :403-408